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Background: Depletion of calcium (Ca2+) from the endoplasmic reticulum (ER) activates the ubiquitous store-
operated Ca2+ entry (SOCE) pathway which sustains long-term Ca2+ signals and is critical for cellular functions.
Stromal interacting molecule 1 (STIM1) serves a dual role as an ER Ca2+ sensor and activator of SOCE. Aberrant
expression of STIM1 could be observed in several human cancer cells. However, the role of STIM1 in regulating
tumorigenesis of human glioblastoma still remains unclear.
Methods: Expression of STIM1 protein in a panel of human glioblastoma cell lines (U251, U87 and U373) in
different transformation level were evaluated by Western blot method. STIM1 loss of function was performed on
U251 cells, derived from grade IV astrocytomas-glioblastoma multiforme with a lentvirus-mediated short harpin RNA
(shRNA) method. The biological impacts after knock down of STIM1 on glioblastoma cells were investigated in vitro
and in vivo.
Results: We discovered that STIM1 protein was expressed in U251, U87 and U373 cells, and especially higher in
U251 cells. RNA interference efficiently downregulated the expression of STIM1 in U251 cells at both mRNA and
protein levels. Specific downregulation of STIM1 inhibited U251 cell proliferation by inducing cell cycle arrest in G0/
G1 phase through regulation of cell cycle-related genes, such as p21Waf1/Cip1, cyclin D1 and cyclin-dependent kinase
4 (CDK4), and the antiproliferative effect of STIM1 silencing was also observed in U251 glioma xenograft tumor
model.
Conclusion: Our findings confirm STIM1 as a rational therapeutic target in human glioblastoma, and also indicate
that lentivirus-mediated STIM1 silencing is a promising therapeutic strategy for human glioblastoma.
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Human glioblastomaBackground
Human glioblastomas are the most common primary tu-
mors of the central nervous system [1]. Despite recent
development had been found in surgical resection, radio-
therapy and chemotherapy, the prognosis has not
changed significantly over the past two decades with a
mean survival of less than twelve months from the time
of diagnosis [2]. Therefore, new treatment strategies for* Correspondence: yanpingweibj@163.com
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reproduction in any medium, provided the orglioblastomas is extremely needed. The increasing know-
ledge about genetic alterations that occur in glioblast-
omas has focused attention on development of targeted
therapy which restore cell cycle or apoptosis defects in
glioma cells. Therefore it could be an attractive alterna-
tive to conventional medicine [3-5].
Calcium (Ca2+) is a multifunctional messenger that
control many cellular processes ranging from short-term
responses such as muscle contraction and secretion to
long-term regulation of cell growth and proliferation
[6,7]. Store-operated Ca2+ entry (SOCE) is a major
mechanism for Ca2+ entry across the cell membrane,
which is stimulated in response to depletion of Ca2+his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reticulum (ER)) and mediated via the activation of
specific plasma membrane channels, termed as store-
operated channels (SOCs) [8]. Stromal interacting mol-
ecule 1 (STIM1) is a highly conserved type-I membrane,
ER-resident protein, containing a luminal EF-hand
Ca2+-binding domain and several cytosolic protein-
protein interaction domains, and serves a dual role as an
ER Ca2+ sensor and activator of SOCE [9-11]. STIM1
initiates the process of store-operated Ca2+ influx by
sensing the deletion of Ca2+ from the lumen of the ER
store. It then migrates to the plasma membrane and
forms aggregates at plasma membrane sites of Ca2+
entry and interacts either directly or in a complex with
the plasma membrane-localized transmembrane protein
Orai1 [9,10].
The role of STIM1 in regulating cancer progression
remains controversial. In early investigations which were
performed prior to the discovery of its role in Ca2+ signal-
ing, STIM1 was described as a tumor suppressor for it
causes growth arrest in human G401 rhabdoid tumor cells
and human RD rhabdomyosarcoma cells [12,13]. However,
subsequent studies revealed a potential role of STIM1 as an
oncogene because it is up-regulated in several human
cancers, such as breast cancer [14], glioblastoma [15,16]
and cervical cancer [17]. Thus, more work needs to be
done to fully determine the role of STIM1 in tumorigenesis
which might vary in different tumor types. In the present
study, we found that expression of STIM1 protein was
higher in U251 and U87 glioblastoma multiforme (both
Grade IV) lines than in U373 astrocytoma (Grade III), par-
ticularly higher in U251 cells [18]. Thus, we applied
lentivirus-mediated small interfering RNA (siRNA) to sup-
press STIM1 expression and investigated the effects of
STIM1 knock down on cell proliferation and cell cycle
progression in U251 cells. Additionally, the proliferation-
related markers (p21Waf1/cip1, Cyclin D1 and CDK4) were
assessed in U251 cells with loss of function of STIM1. As a
proliferation inhibitor, p21Waf1/cip1 was chosen because it is
poised to play an important role in preventing tumor de-
velopment. Cyclin D1-CDK4 complexes promote G1 phase
progression through phosphorylation and inactivation of
the retinoblastoma (Rb) gene product. Our results showed
that specific downregulation of STIM1 inhibited human
glioblastoma cell proliferation and induced G0/G1 phase
cell cycle arrest by increasing expression of p21Waf1/cip1
and decreasing expression of Cyclin D1-CDK4. Therefore,




Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum (FBS), TRIzolW Reagent and Lipofectamine™2000 were purchased from Invitrogen (Carlsbad, CA); 3-
(4,5-dimethylthylthiazol-2yl-)-2,5-diphenyl tetrazolium
bromide (MTT) (Dingguo biology, Shanghai, China);
Dimethylsulfoxide (DMSO) (Shanghai Sibas Biotechnol-
ogy Development Co., Ltd., China); 5-Bromo-2-
deoxyuridine (BrdU) Cell Proliferation ELISA kit was pur-
chased from Roche Applied Sciences (Indianapolis, IN);
Giemsa was purchased from Chemicon International (Te-
mecula, CA); Propidium Iodide (PI) was purchased from
Sigma-Aldrich (St. Louis, MO); Bicinchoninic acid (BCA)
Protein assay was purchased from HyClone-Pierce (South
Logan, UT); M-MLV Reverse Transcription was pur-
chased from Promega (Madison, WI); Oligo-dT was pur-
chased from Sangon Biotech (Shanghai, China); SYBR
green Master Mixture was purchased from Takara (Otsu,
Japan); pFH-L vector and virion-packaging elements
(packing plasmid mix) were obtained from Holybiol
(Shanghai, China). Mouse anti-STIM1, mouse anti-
GAPDH, p21Waf1/Cip1, cyclin D1, cyclin-dependent kinase
4 (CDK4) and goat anti-mouse IgG were purchased from
Santa Cruz biotechnology (Santa Cruz, CA), mouse anti-
STIM2 was purchased from Abcam plc (Abcam, UK),
mouse anti-Orai1 was purchased from Sigma biotechnol-
ogy (Sigma- -Aldrich, US). All other chemicals were of
analytical grade.
Cell culture
Human kidney cell line HEK293,human glioblastoma
cell lines, U251, U87 and U373, were all obtained from
the American Type Culture Collection (ATCC, Manassas,
VA) and cultured in DMEM containing 10% FBS,
100U/mL penicillin and 100 μg/mL streptomycin at
37°C in a humidified atmosphere containing 5% CO2.
siRNA design and construction of recombinant lentiviral
vector
Recombinant lentiviral vector was constructed as de-
scribed previously [19]. The candidate sequence (50-CCT
GGATGATGTAGATCATAA-30) in the STIM1 cDNA
sequence (GenBank accession number NM_003156) was
selected for siRNA and blasted against the human gen-
ome database to eliminate cross-silence phenomenon
with non-target genes. Scrambled siRNA (50-TTCTCC
GAACGTGTCACGT-30) that does not target any genes
was used as the negative control. Short hairpin RNA
(shRNA) was constructed by annealing the synthetic
DNA oligonucleotide primers, then naturally cooled to
room temperature, and inserted between the NheI and
PacI sites of lentiviral expression vector pFH-L which
contains the green fluorescent protein (GFP) gene as a
reporter with an internal CMV promoter. Clone identity
was verified by sequencing.
Considering STIM1 CDS > 2 kb and inefficient expres-
sion of construct RESC lentiviral vector, another shRNA
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chosen to construct to get comparable results. The sense
siRNA sequences were CGGCAGAAGCTGCAGCTGA
and antisense siRNA sequences were TCAGCTGCAGC
TTCTGCCG.
Recombinant lentiviral vector was produced by co-
transfecting HEK293FT cells with lentiviral expression
vector and packing plasmid mix using Lipofectamine™
2000, according to the manufacturer’s instructions. In-
fectious lentiviral particles were harvested at 48 h post-
transfection, centrifuged to get rid off cell debris, and
then filtered through 0.45 μm cellulose acetate filters.
The virus was concentrated by spinning at 4,000 g for
15 min following by a second spin (<1,000 g, 2 min).
The titer of recombinant lentivirus was determined by
serial dilution on 293 T cells.
Recombinant lentivirus transfection in U251 cells
For lentivirus transduction, U251 cells were subcultured
at 5 × 104 cells/well into 6-well culture plates. After
grown to 30% confluence, cells were transducted with
STIM1-siRNA-expressing lentivirus (si-STIM1) or
control-siRNA-expressing lentivirus (si-CTRL) at a
multiplicity of infection (MOI) of 50. Cells were
harvested at 72 h after infection and the transduction ef-
ficiency was evaluated by counting the percentage of
GFP-positive cells.
Quantitative real-time RT-PCR analysis
Total RNA from infected cells was isolated using
TRIzolW Reagent as recommended by the manufacturer.
The quantity and purity of RNA were determined by UV
absorbance spectroscopy. cDNA preparation was per-
formed according to standard procedures using oligo-dT
primer and M-MLV Reverse Transcriptase. Quantitative
real-time PCR was performed by SYBR Green Master
Mixture and analyzed on TAKARA TP800-Thermal Cy-
cler Dice™ Real-Time System. The following primers
were used for STIM1: 50-AGCCTCAGCCATAGTCAC
AG-30 (Forward), 50-TTCCACATCCACATCACCATTG-30
(Reverse); for p21Waf1/Cip1, 50-GGGACAGCAGAGGAAG
ACC-30 (Forward), 50-GACTAAGGCAGAAGATGTAGA
GC-30 (Reverse); for cyclin D1, 50-GGTGGCAAGAGTGT
GGAG-30 (Forward), 50-CCTGGAAGTCAACGGTAGC-30
(Reverse); for CDK4, 50-GAGGCGACTGGAGGCTTTT-30
(Forward), 50-GGATGTGGCACAGACGTCC-30 (Reverse).
Housekeeping gene GAPDH was used as internal con-
trol and the primers are: 50-AGGTCGGAGTCAACGGAT
TTG-30 (Forward), 50-GTGATGGCATGGACTGTGGT-30
(Reverse). Thermal cycling conditions were subjected to
15 s at 95°C and 45 cycles of 5 s at 95°C and 30s at 60°C.
Data was analyzed with TAKARA Thermal Dice Real Time
System software Ver3.0. The gene expression change after
lentivirus transduction was presented as relative expression(fold over the negative control or percentage of the negative
control) after normalizing to GAPDH, and calculated using
the 2-ΔΔCt method as described previously [20].Western blot analysis
Lentivirus-transduced cells were washed twice with
ice-cold PBS and suspended in a lysis buffer (2%
Mercaptoethanol, 20% Glycerol, 4% SDS in 100 mM
Tris-HCl buffer, pH 6.8). After 15 min of incubation on
ice, cells were disrupted by ultrasound on ice. Total cell
lysates were then centrifuged (12,000 g, 15 min, 4°C)
and the supernatants were employed for further process-
ing. The protein concentration was determined by BCA
protein assay kit. Equal amount of proteins was loaded
and separated by SDS-PAGE, and then transferred onto
PVDF membrane (Schleicher&Schuell Co., Keene, NH)
using an electro-blotting apparatus (Tanon, Shanghai,
China). The membrane was blocked with 5% nonfat milk
in TBST solution for 1 h at room temperature, and incu-
bated overnight at 4°C with specific antibody to STIM1,
p21Waf1/Cip1, STIM2, Orai1, cyclin D1 and CDK4 at the
dilution 1:800, 1:1000, 1:800, 1:1000, 1:1500, and 1:1000,
respectively. After three washes in TBST solution, the
membrane was incubated with horseradish peroxidase-
conjugated secondary antibody diluted with TBST solu-
tion at room temperature for 2 h. The signals of
detected proteins were visualized on ECL plus Western
blotting detection system (Amersham Biosciences, Inc.,
Piscataway NJ). GAPDH protein levels were used as a
loading control.MTT cell viability assay and direct cell counting method
Cell viability was determined by a colorimetric MTT
assay which described previously [21]. Briefly, lentivirus-
transduced or TRPC entryway paralysed cells were
seeded in 96-well plates at a density of 2 × 103 cells/well.
Ten microliters of MTT solution (5 mg/mL) was added
into each well once daily for 5 days, and plates were in-
cubated for 4 h at 37°C. After removal of the super-
natant, 100 μL of DMSO was added to dissolve the
crystals. The absorbance at 490 nm was detected with a
microplate reader (Bio-Rad 680). Growth curve was
performed according to the absorbance values (A) of
490 nm.
On the other hand, direct cell counting method was
also used to cross-checking the results of MTT assay.
Double target RNAi U251 cells were seeded in 96-well
plates at a density of 1 × 104 cells/well. After that, num-
ber of cells at 24 h and 48 h after seeding would be
counted by blood cell counting plate. Besides, we count
3 wells for reduce error every time point. Growth curve
was made according to the average number of cells in 3
wells.
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Cell proliferation was also quantified by measuring BrdU
incorporation during DNA synthesis using the BrdU Cell
Proliferation ELISA kit. The experiment was performed
according to the manufacturer’s protocol. Briefly, 10 μL/
well of BrdU labeling solution was added to cells at 24 h
and 72 h after culture. After overnight incubation, cells
were fixed with 200 μL/well of fix solution for 30 min in
the dark at room temperature, and then incubated with
peroxidase-conjugated anti-BrdU antibody for 90 min in
the dark at room temperature. A substrate solution was
then added into each well, and absorbance was mea-
sured using microplate reader (Bio-Rad 680) at a wave-
length of 450 nm with a reference wavelength of
630 nm. The number of proliferating cells is represented
by the level of BrdU incorporation which directly corre-
lates to the absorbance values. Growth rate (R) was
calculated by the following equation:
R ¼ A72hA24hð Þ=A24h  100;
where A72h and A24h indicate the absorbance at 450 nm
after 24 and 72 hours of incubation.
Colony formation assay
Lentivirus-transduced glioblastoma cells (200 cells/ well)
were seeded in 6-well plates. Culture medium was
changed at regular time intervals. After 14 days of cul-
ture, adherent cells were washed twice with PBS, fixed
with 4% paraformaldehyde for 30 min at room
temperature. The colonies were stained with Giemsa so-
lution for 15 min, then washed with water and air-dried.
Cell colonies were counted using a light microscopy.
The experiment was performed in triplicate.
Cell cycle analysis
The effect of STIM1 on cell cycle distribution was deter-
mined by flow cytometry [22]. Briefly, lentivirus-
transduced U251 cells (1 × 105 cells/dish) were seeded at
6-cm dishes. Cells were harvested when they reach 80%
confluence, and fixed at least 1 h with 70% ice-cold etha-
nol at 4°C. Cells were washed with PBS and resuspended
in 1 mL of PBS containing 50 μg/mL PI and 100 μg/mL
RNase A. After following incubation for 1 h in the dark
at room temperature, cells were analyzed by flow cytometry
using a FACSCalibur flow cytometer (Becton-Dickinson,
San Jose, CA) at 24, 48 and 72 hrs after transduction.
The fractions of cells in G0/G1, S, and G2/M phases were
analyzed using dedicated software.
Xenograft tumor model
The antitumor effects of siSTIM1 were evaluated in vivo
using the U251 human glioma xenograft model in nude
mice. All animal procedures were performed accordingto the guidelines of Peking Union Medical College Hospital,
Peking Union Medical College and Chinese Academy of
Medical Sciences. Briefly, U251 cells were infected with si-
STIM1-expressing lentivirus or control-siRNA-expressing
lentivirus at MOI of 50. When an apparent efficiency of
80%-90% GFP-positive cells was observed, cells were
harvested and suspended at a density of 2 × 107/mL
DMEM (without serum), and 5 × 106 cells were subcutane-
ously injected into the right dorsal flank of male BALB/c
nu/nu athymic nude mice (SLAC Laboratory Animal Co.
Ltd., Shanghai, China, 4-6 week-old) (n = 10 per group).
The mice were housed and maintained under specific-
pathogen free (SPF) condition. Tumor size was measured
every 10 days using microcaliper, and tumor volume was
calculated according to the following formula: tumor
volume = (width2 × length)/2. The animals were sacrificed
and tumors were excised after 30 days after injection.
Tumor size was measured, and then the tumor was imme-
diately frozen in liquid N2 for protein extraction.
Protein extraction of xenograft tumors
Tumor tissue (approximate 5 mg) frozen in liquid N2 was
manually homogenized on ice, lysed in lysis buffer
supplemented with protease inhibitors, and then incubated
on ice for 2 h. The supernatants were cleared by centrifu-
gation (12,000 rpm, 20 min, 4°C). Protein extracts were
used for assessing expression of STIM1 protein in the
tumor samples by Western blot which described above.
Statistical analysis
Data were expressed as the mean ± standard deviation
(SD) of at least three independment experiments. The
results were analyzed by Student’s t-test, and P < 0.05
was considered statistically significant.
Ethical approval
All experimental research that is reported in the manu-
script have been performed with the approval of Institu-
tional Ethics Committee of Peking Union Medical College
Hospital. Research carried out on humans be in compliance
with the Helsinki Declaration, and all experimental research
on animals follow internationally recognized guidelines.
Results and discussion
Expression of STIM1in human glioblastoma cell lines and
HEK293 cell
To investigate the role of STIM1 in the malignant devel-
opment of gliomas, we compared the expression levels
of STIM1 protein in HEK293 cell and human glioblast-
omas cell lines in different transformation degree, as
represented by U373 astrocytoma (WHO Grade III),
U87 and U251 glioblastoma multiforme (WHO grade
IV) lines by Western blot analysis. Of note, we chose
HEK293 cell as a negative control of a non-tumor cell
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Figure 1A, U251 cells, derived from a high-grade glio-
blastoma, showed higher expression of STIM1; there-
fore, U251 cells represent a reasonable cell culture
system for experimental validations of data and were
selected in the following loss of function experiments.
Lentivirus-mediated siRNA targeting STIM1 inhibited
STIM1 expression in U251 cells
To address the question of whether STIM1 could serve as
a therapeutic target for human glioblastoma, we employed
RNA interference (RNAi) method in an attempt to inhibit
the expression of STIM1 in U251 cells. The efficiency of
lentivirus transduction in U251 cells was examined by
fluorescent microscopy, and more than 90% of the cells
were infected with si-STIM1 at 72 hrs post-transduction
at MOI of 50 as indicated by the expression of GFP
(Figure 1B). To determine the knock down efficiency of
STIM1, quantitative real-time RT-PCR and Western blot
analysis were performed. As shown in Figure 1C, mRNAFigure 1 Lentivirus-mediated siRNA inhibited STIM1 expression
in U251 cells. (A) Western blot assay: STIM1 protein is expressed in
HEK293 cell and human glioblastoma cell lines of different
transformation degree, as represented by U373 astrocytoma (WHO
Grade III), U87 and U251 glioblastoma multiforme (WHO Grade IV)
lines. (B) Transduction efficiency was estimated 72 hrs after
transduction at MOI of 50. GFP expression in infected cells was
observed under light microscope and fluorescence microscope.
Light micrograph (top); Fluorescent micrograph (bottom) (×100).
(C) Total RNA was extracted at 72 hrs after transduction and relative
STIM1 mRNA expression was determined by quantitative real-time
RT-PCR. GAPDH were used to standardize results. Data represent the
mean ± S.D. of three independent experiments. **P < 0.01, compared
with the si-CTRL group. (D) Total cellular proteins were extracted at
72 hrs after transduction and determined by Western blot analysis
using antibodies against STIM1, Orai1, STIM2, with GAPDH as an
internal control. Data represent one out of three separate
experiments. si-CTRL: cells infected with control-siRNA-expressing
lentivirus; si-STIM1: cells infected with si-STIM1.level of STIM1 in cells that infected with si-STIM1 was sig-
nificantly decreased about 89.7% ± 3.8% compared with that
in cells infected with control-siRNA-expressing lentivirus
(si-CTRL) 72 hrs after transduction (**P < 0.01). Addition-
ally, Western blot analysis was also performed 72 hrs after
lentivirus transduction. Expression of STIM1 protein was
significantly reduced in the si-STIM1 group in comparison
to si-CTRL group while little effect on the expression of
Orai1, and expression of STIM2 was compensatorily risen
to a certain extent. (Figure 1D). Totally, these results indi-
cated that lentivirus-mediated siRNA efficiently and specif-
ically suppressed STIM1 expression in U251 cells.
Suppression of STIM1 inhibited U251 cell proliferation
The effect of down-regulation of STIM1 on proliferation
of glioblastoma cells in vitro was assessed by MTT assay,
BrdU incorporation assay and colony formation assay.
Firstly, the amount of cell proliferation was determined
using the MTT assay once daily for 5 days. As shown
in Figure 2A, STIM1 silencing inhibited U251 cellFigure 2 Effect of STIM1 silencing on U251 cell proliferation.
(A) Cell proliferation of lentivirus-transduced and TRPC entryway
paralysed U251 cell were measured by MTT assay once daily. Cell
proliferation was expressed as the absorbance values. (B) DNA
synthesis was measured by BrdU incorporation assay at 24 h and
72 h after transduction. Growth rate (R) was calculated by the
following equation to reflect the role of STIM1 in DNA synthesis
ability: R = (A72h - A24h) / A24h × 100 where A72h and A24h indicate
the absorbance at 450 nm after 24 and 72 hrs of incubation. (C), (D)
Detection of cell proliferation by plate colony formation assay in
U251 and U373cells. Representative photographs showing U251 and
U373 cell colony in 6-well plate. U251 and U373 cells were seeded
at 200 per well and allowed to form colonies. Cell colonies were
scored visually and counted using a light microscopy. Data
represent the mean ± S.D. of three independent experiments.
**P < 0.01 compared with the si-CTRL group. si-CTRL: cells infected
with control-siRNA-expressing lentivirus; si-STIM1: cells infected
with si-STIM1.
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pared with the si-CTRL group, the cell number in si-
STIM1 group was significantly reduced by 43.6% ± 3.5%
(**P < 0.01) at 5 days post-transduction. Besides, after
performed TRPC entryway paralysor SKF9636 in U251
cell, the malignant proliferation of U251 cell was observ-
ably slow down compared with CTRL group. The cell pro-
liferation of U373 and U87 cells were shown in Additional
file 1: Figure S1A and S1B. They had the same tendency
compare with U251 cell. Cell proliferative activity was then
assessed by BrdU incorporation into cellular DNA.
Figure 2B shows a significant decrease the growth rate of
U252 cells in si-STIM1 group (33.6% ± 5.8%) in compari-
son to si-CTRL group (78.1% ± 4.0%) (** P < 0.01).
At the same time, results of double target RNAi U251
cell viability detected by MTT assay and direct cell
counting method were shown in Additional file 2: Figure
S2A and S2B. They had the same tendency. And then,
we detected expression levels of STIM1 protein by
Western blot which could be seen in Additional file 2:
Figure S2C.
Furthermore, the colony formation capacity in U251,
U373 cells which infected with si-STIM1 or si-CTRL
lentivirus was estimated at 14 days after transduction.
As shown in Figure 2C and 2D, the number of U251 cell
colonies in the si-STIM1 group (19) was reduced by
63.8% ± 4.6% (**P < 0.01) in comparison to the si-CTRL
group (48) . The colony formation capacity in U373 cells
was also shown in Figure 2C and 2D.Figure 3 Effect of downregulation of STIM1 on cell cycle progression
cytometric analysis. (A) Representative flow cytometric histograms at 24 hr
cytometric histograms at 48 hrs showing the distribution of cell cycle. (C) R
distribution of cell cycle. (D) Knockdown of STIM1 by RNAi in U251 cells ind
(E) Knockdown of STIM1 by RNAi in U251 cells induced cell cycle arrest in
RNAi in U251 cells induced cell cycle arrest in G0/G1 phase at 72 hrs afterCollectively, these results showed that knock down of
STIM1 by lentivirus-mediated siRNA could inhibit U251
cell proliferation in vitro.
Suppression of STIM1 induced cell cycle arrest in G0/G1
phase and alterant expression levels of cell cycle-related
genes in U251 cells
To further elucidate the growth suppression effect of si-
STIM1 on U251 cells, we performed cell cycle distribu-
tion analysis by flow cytometry at 24, 48 and 72 hrs after
transduction. As shown in Figure 3A, 3B and 3C, STIM1
knockdown induced cell cycle arrest in G0/G1 phase in
U251 cells. When compared with the si-CTRL group,
the percentage of G0/G1 phase in the si-STIM1 group
was increased by 1.9% (*P < 0.05) at 48 hrs; what’s more,
the percentage of G0/G1 phase in the si-STIM1 group
was increased by 5.6% (*P < 0.05) at 72 hrs. The result
demonstrate that STIM1 silencing may induce cell cycle
arrest at G0/G1 phase and the effection of STIM1 on
cell cycle does have time dependence.
We next performed real-time RT-PCR and Western
blot analysis to assess the mRNA and protein levels of
cell cycle-related molecules. After 72 hrs of transduction,
RNAi-mediated STIM1 silencing induced upregulation
of p21waf1/cip1 and downregulation of cyclin D1 and
CDK4 simultaneously in U251 cells (Figure 4A and 4B).
The results demonstrated that STIM1 may be involved
in regulating the expression of cyclins-cyclin-dependent
kinases (CDKs)-CDK inhibitors (CDKIs) in U251 cells.in U251 cells. Cell cycle distribution was performed by flow
s showing the distribution of cell cycle. (B) Representative flow
epresentative flow cytometric histograms at 72 hrs showing the
uced cell cycle arrest in G0/G1 phase at 24 hrs after transduction.
G0/G1 phase at 48 hrs after transduction. (F) Knockdown of STIM1 by
transduction.
Figure 4 mRNA and protein levels of cell cycle-related molecules. (A) Total RNA was extracted at 72 hrs after transduction and mRNA
expression of p21Waf1/Cip1, cyclin D1 and CDK4 was determined by quantitative real-time RT-PCR. GAPDH was used as an internal control. (B) Total
cellular protein were extracted at 72 hrs after transduction and determined by Western blot analysis using antibodies against p21Waf1/Cip1, cyclin
D1 and CDK4, and GAPDH as a loading control. Data represent the mean ± S.D. of three independent experiments. *P <0.05, **P < 0.01 compared
with the si-CTRL group. si-CTRL: cells infected with control-siRNA-expressing lentivirus; si-STIM1: cells infected with si-STIM1.
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To determine whether STIM1 silencing could inhibit
tumor development in vivo, lentivirus transduced U251
cells were subcutaneously injected into the right dorsal
flank of the nude mice and tumor growth was evaluated.
As shown in Figure 5A, the average growth rate of the
ten si-STIM1 xenografts was reduced by 41.9% ± 5.7%
(**P < 0.001, day 30) compare with control tumors (si-
CTRL) as assessed by serial microcaliper measurements.
si-STIM1 tumors that were resected on day 30 post-
inoculation weighed 50% less than si-CTRL tumors
(*P < 0.05) (Figure 5B). Representative photographs of
mice in two groups (si-STIM1 and si-CTRL) and their
transplanted tumors were shown in Figure 5C. Western blot
analysis verified that STIM1 levels remained downregulation
in the si-STIM1 transduced U251 xenografts in comparison
to the control (Figure 5D). Thus, these results indicated
that lentivirus-mediated gene silencing of STIM1 may be
a promising therapeutic strategy for human glioblastoma.
Discussion
SOCE, also known as capacitative Ca2+ entry, is thought
to have an essential role in the regulation of contraction,
cell proliferation, and apoptosis [23-25]. As a Ca2+ sen-
sor in the ER, STIM1 is capable of triggering a cascade
of reactions leading to SOCE activation [8], and involved
in control of nontumorous cell proliferation [26-28].
Several studies have shown that STIM1 is overexpressed
in human glioblastoma [15,16], but the molecular mech-
anism was not identified. Its role in regulating cancer
cell proliferation and progression may be indirect and
dependent on other Ca2+ entry proteins. Recent study by
Liu et al. shows that calcium release-activated calcium
(CRAC) channels regulate glioblastoma cell prolifera-
tion. Both Orai1 and STIM1 knockdown inducedsustained proliferation inhibition in glioma C6 cells by
using siRNA technology, being the effect of Orai1 silen-
cing more prominent than that of STIM1 silencing [15].
Furthermore, Bomben and Sontheimer have recently
shown that silencing the expression of TRPC1, a mem-
ber of the family of TRPC channels also involved in
SOCE, inhibits the proliferation of D54MG glioma cells
and in vivo tumor growth [29].
In the present study, we found that STIM1 protein
was expressed in human glioblastomas cell of different
transformation degree, especially higher expressed in
U251 cells that were derived from a high-grade glioblast-
oma; therefore, these phenomenon represent a reason-
able cell culture system for STIM1 loss of function
experiment. We employ lentivirus-mediated siRNA to
suppress STIM1 expression in U251 cells. More than
90% of the cells were infected at MOI of 50 as indicated
by the expression of GFP at 72 hrs post-transduction
(Figure 1B). Both STIM1 mRNA and protein expression
levels in U251 cells were downregulated (Figure 1C and
1D). Furthermore, knockdown of STIM1 inhibited U251
cell proliferation by inducing cell cycle arrest in G0/G1
phase in vitro, and this inhibition of proliferation would
be in connection with damage of functional integrity of
Ca2+ which induced by STIM1 knock-down (Figures 2
and 3). Through U251 xenograft model in nude mice,
we found that STIM1 silencing also significantly affect
tumor growth in vivo (Figure 4). Thus, these findings
showed that STIM1 silencing resulted in changes in cell
cycle progression and exhibited in vivo effects in
tumorigenesis.
Deregulated cell cycle progression is one of the pri-
mary characteristics of cancer cells [30]. Cell cycle pro-
gression involves sequential activation of CDKs whose
association with corresponding regulatory cyclins is
necessary for their activation [31,32]. As a critical
Figure 5 Effect of STIM1 knockdown on tumorigenicity in nude mice. U251 cells transduction with si-STIM1 or siCTRL were subcutaneously
injected into the right dorsal flank of the nude mice as described in Materials and methods. Tumor volume was determined on Day 10, 20 and 30. At the
end of the experiment, animals were sacrificed and tumors were excised for weight measurement and Western blot analysis. (A) Growth curve of tumor
xenografts was assessed by serial microcaliper measurements. (B) Weight of tumor xenografts 30 days after inoculation. (C) Representative photographs of
mice and tumors for each treatment. (D) Total protein from the resected tumors were prepared and used to determine the expression of STIM1 by
Western blot analysis using antibodies against STIM1 and GAPDH. Data represent the mean ± S.D. of three independent experiments. *P <0.05, **P< 0.01
compared with the si-CTRL group. si-CTRL: cells infected with control-siRNA-expressing lentivirus; si-STIM1: cells infected with si-STIM1.
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Cyclin D1 in cancer cells resulted in an uncontrolled
growth advantage. Cyclin D-CDK4/CDK6 and cyclin E-
CDK2 complexes regulate cell cycle entry from G1 to S
phase, phosphorylate and inactivate the retinoblastoma
(Rb) protein. Upon phosphorylation, Rb dissociates from
E2F family of transcription factors and allows for E2F-
dependent transcription to occur [33]. As shown in
Figure 3C and 3D, STIM1 silencing in U251 cells resulted
in a marked decrease in the expression of cyclin D1
and CDK4. On the other hand, the CDKIs p21 waf1/cip1 and
p27 kip1 regulate the progression of cells in the G0/G1
phase of the cell cycle and induction of these proteins
causes a blockade of the G1 to S transition, thereby
resulting in a G0/G1 phase arrest of the cell cycle [34]. The
loss of CDKI in human cancers leads to uncontrolled cell
proliferation which due to an increase in the levels of the
CDK-cyclin complex [35]. In present study, STIM1 silen-
cing caused a marked increase in expression of p21 waf1/cip1
in U251 cells (Figure 3C and 3D). These observations
suggest that STIM1 may play an important role in cell cycle
progression of human glioblastoma by regulating the
cyclins-CDKs-CDKIs expression.
The mechanisms linked to the inhibition of cell prolif-
eration and tumor growth after STIM1 silencing were
rather similar to our previous report which we show that
RNAi-mediated silencing of the protein iASPP alsoresults in G0/G1 cell cycle arrest in glioblastoma U251
cells, with concomitant changes in the expression of cyc-
lin D1 and p21wafl/cip1 [36]. However, subsequent study
of the signaling pathway which regulates STIM1 func-
tion in glioblastoma still needs to be elucidated.
Conclusions
In conclusion, we report that STIM1 is expressed in human
glioma cell lines derived from a high-grade glioblastoma.
RNAi-mediated gene silencing of STIM1 suppresses U251
cell growth both in vitro and in vivo, and blocks cell cycle
progression at the G0/G1 phase. The anticancer effect of
STIM1 silencing is likely mediated through the regulation
of a large number of genes involved in cell cycle control,
including p21Waf1/Cip1, cyclin D1 and CDK4. Thus, our
findings illustrate the biological significance of STIM1 in
tumorigenesis of glioma, and provide evidences that
STIM1 may be a potential therapeutic target for human
glioblastoma.
Additional files
Additional file 1: Figure S1. Effect of STIM1 silencing on U87 and
U373 cell proliferation. (A) Cell proliferation of lentivirus-transduced U87
cell were measured by MTT assay once daily. (B) Cell proliferation of
lentivirus-transduced U373 cell were measured by MTT assay once daily.
Cell proliferation was expressed as the absorbance values.
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